XML 20 R5.htm IDEA: XBRL DOCUMENT v3.6.0.2
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Operating Activities    
Net income $ 58,305 $ 85,971
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 18,700 17,478
Loss on divestitures and sales of property and equipment 51,807 0
Deferred income taxes (12,530) 31,591
Amortization of debt origination costs 6,129 5,433
Stock-based compensation costs 6,260 7,098
Loss on extinguishment of debt 0 451
Gain on sale or disposal of property and equipment 0 (36)
Changes in operating assets and liabilities, net of effects from acquisitions:    
Accounts receivable (12,374) 2,453
Inventories (16,589) (7,114)
Prepaid expenses and other current assets 11,149 5,472
Accounts payable 7,168 (17,553)
Accrued liabilities 22,323 5,207
Net cash provided by operating activities 140,348 136,451
Investing Activities    
Purchases of property and equipment (1,935) (2,540)
Proceeds from divestitures 110,717 0
Proceeds from the sales of property and equipment 85 344
Net cash provided by investing activities 110,286 5,041
Financing Activities    
Term loan repayments (130,500) (50,000)
Borrowings under revolving credit agreement 20,000 15,000
Repayments under revolving credit agreement (105,000) (81,100)
Payments of debt origination costs (9) (4,211)
Proceeds from exercise of stock options 3,444 6,600
Proceeds from restricted stock exercises 0 544
Excess tax benefits from share-based awards 800 1,850
Fair value of shares surrendered as payment of tax withholding (1,431) (2,187)
Net cash used in financing activities (212,696) (113,504)
Effects of exchange rate changes on cash and cash equivalents (1,879) (333)
Increase in cash and cash equivalents 36,059 27,655
Cash and cash equivalents - beginning of period 27,230 21,318
Cash and cash equivalents - end of period 63,289 48,973
Interest paid 54,615 58,867
Income taxes paid 25,127 9,014
Insight Pharmaceuticals    
Investing Activities    
Proceeds from previous acquisitions 0 7,237
DenTek Oral Care, Inc.    
Investing Activities    
Proceeds from previous acquisitions $ 1,419 $ 0